Generic Name and Formulations:
Ioxilan 300mgI/mL, 350mgI/mL; soln for IV inj; preservative-free.
Indications for OXILAN:
Intraarterial: For cerebral arteriography (300mgI/mL). For coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography (350mgI/mL). IV: For excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300mgI/mL and 350mgI/mL).
Individualize. Intraarterial procedures: Left and right coronary: 2–10mL. Left ventricle: 25–50mL. Aortography and selective visceral: see literature. Aortic bifurcation for distal runoff: 45–100mL. Subclavian or femoral artery: 10–40mL. Total dose for procedure should not exceed 250mL. Cerebral arteriography: 8–12mL; total dose for procedure should not exceed 150mL. IV procedures: Excretory urography: 250–390mgI/kg; total dose for procedure should not exceed 100mL. CECT of the head: 100–200mL (300mgI/mL) or 86–172mL (350mgI/mL); total dose for procedure should not exceed 200mL. CECT of body: 50–200mL (300mgI/mL) or 43–172mL (350mgI/mL); total dose for procedure should not exceed 200mL.
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune disorders. Maintain adequate hydration. History of sever cutaneous hypersensitivity reaction; avoid. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Nonionic contrast agent.
Headache, fever, hematoma at inj site, chills, angina, hypertension, bradycardia, hypotension, GI upset, dizziness, urticaria, rash; thromboembolic events, hypersensitivity reactions, severe cutaneous reactions (eg, SJS/TEN, AGEP, DRESS).
Single-dose bottles (50mL, 100mL, 150mL, 200mL)—10
Endocrinology Advisor Articles
- FDA Approves Admelog Short-Acting Insulin Lispro Injection
- Fertility Hormone Therapy and Cardiovascular Outcomes: What We Know
- Effects of Peer Influence in Adolescents With Type 1 Diabetes
- More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes
- One-Hour Glucose Readings Predict T2D Risk Better Than 2-Hour Measurements
- FDA: Vitamin B7 May Interfere With Lab Tests for Hormone Levels
- Injected and Oral Medications Equally Safe for Gestational Diabetes
- Adjunctive Dapagliflozin Improves Glycemic Control in T1D
- Estradiol Therapy May Benefit Overall Cognition in Postmenopausal Women
- Stopping Postmenopausal HT May Increase Risk for Cardiac, Stroke Death
- Psychosocial Benefits of a Bihormonal Bionic Pancreas System in T1D
- Safety of Chronic Total Occlusion Percutaneous Coronary Intervention in Diabetes
- Oral Insulin Not a Reliable Preventive Strategy for Type 1 Diabetes
- Prevention of Bone Mineral Density Loss Needed in Epilepsy
- Gastric Bypass Blunts B-Cell Sensitivity During Glycemia